• Explore /
  • Poster
  • / A randomized, double-blind, placebo-controlled trial of trametinib, a MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas.

A randomized, double-blind, placebo-controlled trial of trametinib, a MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas.

Abstract Poster

Authors

null

Jeffrey Infante

Sarah Cannon Research Institute/Tennessee Oncology

Jeffrey Infante , Bradley Somer , Joon Oh Park , Chung-Pin Li , Max Scheulen , Saifuddin Kasubhai , Do-Youn Oh , Yuan Liu , Soumi Lahiri , Klaudia Steplewski , Ngocdiep Le

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2013 Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

General Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Track

Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Sub Track

Multidisciplinary Treatment

Clinical Trial Registration Number

NCT01231581

Citation

J Clin Oncol 31, 2013 (suppl 4; abstr291)

DOI

10.1200/jco.2013.31.4_suppl.291

Abstract #

291

Poster Bd #

C39

Abstract Disclosures

Similar Posters

First Author: John Heymach

First Author: Eric Van Cutsem

First Author: Aaron James Scott

First Author: Hanno Riess